GA Depot is intended for the treatment of relapsing forms of multiple sclerosis. Credit: Zerbor/Shutterstock.com.

The US Food and Drug Administration (FDA) has accepted for review Viatris and Mapi Pharma’s new drug application (NDA) which has been filed for GA Depot.

A Prescription Drug User Fee Act target action date of 8 March 2024 was assigned by the FDA.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The 40mg product is a long-acting glatiramer acetate (GA) to treat relapsing forms of multiple sclerosis (RMS/MS). It is administered as a monthly injection.

The filing is supported by data from a Phase III study that compared the safety, tolerability and efficacy of GA Depot with placebo.

This multinational, double-blind, placebo-controlled study enrolled 1,016 subjects who received either 40mg of GA Depot or a placebo.

Both groups received the treatment once every four weeks for a total of 13 doses via intramuscular injection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The product offered a preferable schedule and anticipated fewer injection site reactions than other GA candidates.

A statistically significantly reduced annualised relapse rate of 30.1% against placebo (p=0.0066) was observed, a primary endpoint of the study.

Mapi Pharma CEO and chairman Ehud Marom stated: “We are confident that GA Depot, when approved, will represent an important advancement in MS care by offering a convenient once-monthly option for patients which may potentially improve compliance and adherence, and the medicine is well positioned to deliver on this important unmet need.

“I commend the teams at Mapi and Viatris for the strong collaboration which has leveraged our collective expertise in complex products to deliver this novel medicine.”

Commercially available as Copaxon, GA Depot is a long-acting injection version of the approved GA.

It is also currently being studied in a Phase II trial in patients with primary progressive multiple sclerosis.